XI’AN, China, May 16, 2025 — Bon Natural Life Limited (Nasdaq: BON) (“BON” or the “Company”), a leading provider of bio-ingredient solutions for the natural, health, and personal care sectors, has announced an exclusive 36-month cooperation agreement valued at $32 million with Beijing Huahai Keyuan (Tech) Co., Ltd., a prominent distributor of functional ingredients in China. As per the agreement, Beijing Huahai Keyuan will be the exclusive sales partner for BON’s postbiotic hypoglycemic ingredients. BON intends to penetrate the global blood sugar health market by creating a line of innovative hypoglycemic products.

BON’s patented postbiotic hypoglycemic ingredient is formulated to regulate blood sugar levels, providing targeted control over post-meal glucose spikes and reducing blood sugar surges. It is highly effective, safe, convenient, and easily integrated into daily routines, which promotes strong user adherence. The company believes that these advantages will allow the postbiotic hypoglycemic ingredient to transform the postprandial blood sugar control market and gain a significant market share.

Current market data shows that the postprandial blood glucose control market is expanding rapidly, exceeding $30 billion with a compound annual growth rate of 7.5%¹.

Hu Yongwei, Chairman and CEO of BON, commented, “Leveraging BON’s product capabilities and our partners’ market strengths, we are confident in our ability to succeed and establish a leading position in the large and rapidly growing postprandial blood glucose control market, as we hold the patent for postbiotics with groundbreaking technological advantages. The Company expects that its postbiotic-based hypoglycemic product line will make significant market progress over the next 2-3 years, leading to rapid sales and profit growth and enhancing the Company’s investment value. Furthermore, the growth of this business will accelerate the Company’s emergence as a key player in blood glucose health, a vital area within the wider healthcare industry, positioning it as a leader in comprehensive blood glucose health solutions.”

About Bon Natural Life Limited (“BON”)

BON, a Cayman Islands-based company, operates in the natural, health, and personal care industries. Additional information is available on the Company’s website at http://www.bnlus.com.

For more information, please contact:

Cindy Liu | IR
Email: bonnatural@appchem.cn

Safe Harbor Statement

This press release includes statements that may be considered “forward-looking statements.” All statements that are not historical facts are forward-looking statements. These statements are often identified by terms such as “believes,” “expects,” or similar language and involve known and unknown risks and uncertainties. Although the Company believes its forward-looking statements are reasonable, they are based on assumptions, risks, and uncertainties, and actual results may differ materially. Readers should not unduly rely on these forward-looking statements, which are relevant only as of the date of this press release. The Company’s actual results could differ materially from those anticipated due to various factors, including those discussed in the Company’s filings with the Securities and Exchange Commission, available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or its representatives are expressly qualified by these factors. The Company undertakes no obligation to update these forward-looking statements, except as required by securities laws.

_______________________
1. IQVIA “Global Diabetes Treatment Market Outlook 2025